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Introduction
Hennekam syndrome (OMIM #235510 and #616006) is an auto-
somal-recessive disorder characterized by congenital lymphede-
ma and lymphangiectasia, unusual facial morphology, attribut-
ed at least in part to intrauterine facial lymphedema, and a 
variable degree of intellectual disability (1–3). Approximately 25% 
of patients with Hennekam syndrome have been found to have 
mutations in CCBE1 (4), encoding collagen and calcium binding 
EGF domains 1, a secreted matrix protein that facilitates the pro-
teolytic cleavage and activation of VEGF-C (5–7). ADAM metal-
lopeptidase with thrombospondin type 1 motif 3 (ADAMTS3) 
cooperates with CCBE1 by proteolytically cleaving and activating 
VEGF-C (8), and mutations in ADAMTS3 were recently shown to 
underlie Hennekam syndrome (9). The VEGF-C/VEGFR3 sig-
naling axis is of paramount importance for lymphangiogenesis 
(10, 11); VEGF-C is crucial for the exit and guidance of lymphatic 
endothelial progenitor cells from the embryonic veins to form the 
initial lymphatic vascular plexus (12), and VEGFR3, expressed by 
lymphatic endothelial cells (LECs), transduces VEGF-C–initiated 
signals to mediate LEC migration and proliferation (13, 14). Het-
erozygous loss-of-function mutations in both VEGFC (15, 16) and 
Fms-related receptor tyrosine kinase 4 (FLT4), encoding VEGFR3 
(12, 17–19), underlie human hereditary lymphedema, and muta-
tions in genes involved in the VEGFR3 signaling pathway have 
been estimated to cause approximately 36% of primary lymph-
edema cases (20). Recently, FAT4 mutations were documented in 
patients with Hennekam syndrome in whom no CCBE1 mutations 
were detected (21), a discovery that uncovered an important role 
for FAT4 in the lymphatic vasculature. Moreover, this discovery 
suggested that FAT4, CCBE1, and ADAMTS3 might be compo-
nents of the same signaling pathway.
FAT4 is the closest vertebrate homolog of Drosophila fat (ft) 
(22, 23), an extremely large, atypical cadherin with roles in the con-
trol of planar cell polarity (PCP) and regulation of Hippo pathway 
signaling (24). These roles appear largely conserved in mammali-
an Fat4, although they are tissue dependent; Fat4–/– mice die soon 
after birth and exhibit defective PCP in tissues including kidney, 
inner ear, neural tube (25), facial branchiomotor neurons (26), and 
sternum (27), whereas aberrant Hippo pathway activity, leading 
to elevated cell proliferation, has been reported in Fat4-deficient 
nephron progenitor cells (28), embryonic neuroepithelium (29), 
The atypical cadherin FAT4 has established roles in the regulation of planar cell polarity and Hippo pathway signaling 
that are cell context dependent. The recent identification of FAT4 mutations in Hennekam syndrome, features of which 
include lymphedema, lymphangiectasia, and mental retardation, uncovered an important role for FAT4 in the lymphatic 
vasculature. Hennekam syndrome is also caused by mutations in collagen and calcium binding EGF domains 1 (CCBE1) 
and ADAM metallopeptidase with thrombospondin type 1 motif 3 (ADAMTS3), encoding a matrix protein and protease, 
respectively, that regulate activity of the key prolymphangiogenic VEGF-C/VEGFR3 signaling axis by facilitating the 
proteolytic cleavage and activation of VEGF-C. The fact that FAT4, CCBE1, and ADAMTS3 mutations underlie Hennekam 
syndrome suggested that all 3 genes might function in a common pathway. We identified FAT4 as a target gene of GATA-
binding protein 2 (GATA2), a key transcriptional regulator of lymphatic vascular development and, in particular, lymphatic 
vessel valve development. Here, we demonstrate that FAT4 functions in a lymphatic endothelial cell–autonomous manner 
to control cell polarity in response to flow and is required for lymphatic vessel morphogenesis throughout development. 
Our data reveal a crucial role for FAT4 in lymphangiogenesis and shed light on the mechanistic basis by which FAT4 
mutations underlie a human lymphedema syndrome.
Atypical cadherin FAT4 orchestrates lymphatic 
endothelial cell polarity in response to flow 
Kelly L. Betterman,1,2 Drew L. Sutton,1,2 Genevieve A. Secker,1,2 Jan Kazenwadel,1,2 Anna Oszmiana,1,2 Lillian Lim,3 Naoyuki Miura,4 
Lydia Sorokin,5 Benjamin M. Hogan,6,7,8 Mark L. Kahn,3 Helen McNeill,9,10,11 and Natasha L. Harvey1,2
1Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, South Australia, Australia. 2SA Pathology, Adelaide, South Australia, Australia. 3Department of Medicine and 
Cardiovascular Institute, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 4Department of Biochemistry, Hamamatsu University School of Medicine, Hamamatsu, Japan. 5Institute of 
Physiological Chemistry and Pathobiochemistry, University of Muenster, Muenster, Germany. 6Division of Genomics of Development and Disease, Institute for Molecular Bioscience, University of Queensland, 
Saint Lucia, Queensland, Australia. 7Organogenesis and Cancer Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. 8Department of Anatomy and Neuroscience, University of Melbourne, 
Melbourne, Victoria, Australia. 9Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada. 10Department of Molecular Genetics, University of Toronto, Toronto, Ontario, 
Canada. 11Department of Developmental Biology, Washington University School of Medicine, Saint Louis, Missouri, USA.
Authorship note: KLB and DLS share co–first authorship.
Conflict of interest: The authors have declared that no conflict of interest exists.
Copyright: © 2020, American Society for Clinical Investigation.
Submitted: December 11, 2017; Accepted: March 5, 2020; Published: May 18, 2020.
Reference information: J Clin Invest. 2020;130(6):3315–3328. 
https://doi.org/10.1172/JCI99027.
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
3 3 1 6 jci.org   Volume 130   Number 6   June 2020
onic LECs (mLECs). Analysis of the genes most significantly 
decreased in expression revealed that both Fat4 and Dchs1, encod-
ing the large atypical cadherins FAT4 and DCHS1, were substan-
tially decreased upon GATA2 knockdown. We next confirmed that 
FAT4 and DCHS1 were reduced in GATA2 siRNA–treated primary 
human LECs (hLECs); as expected, expression of both genes was 
decreased (Figure 1A). In the case of FAT4, this was also con-
firmed at the protein level, as FAT4 expression was reduced by 
approximately 55% in GATA2-deficient cells (Figure 1, B and C). 
Analysis of the genome-wide binding profile of GATA2 in hLECs 
revealed that FAT4 is probably directly regulated by GATA2; 
prominent GATA2 binding peaks were identified within the first 
intron of FAT4 (Figure 1D). Given the recent description of FAT4 
mutations in Hennekam syndrome (21), features of which include 
lymphedema and lymphangiectasia (1), we focused on defining 
the role of Fat4 in lymphatic vascular development.
Fat4 is important for lymphatic vessel morphogenesis during 
development. Fat4-deficient mice have been reported to die soon 
after birth and exhibit features consistent with disrupted PCP sig-
naling including cystic kidneys, a shortened body axis, and aber-
rant inner ear hair cell organization (25). To determine whether 
Fat4 is important for lymphatic vascular development, we inves-
tigated lymphangiogenesis throughout development in Fat4Δ/Δ 
mice, generated by crossing Fat4fl/fl mice (25) with CMV-Cre mice 
(34). Analysis of Fat4Δ/Δ embryos at E14.5 revealed that, in contrast 
to their littermate controls (Figure 2A), the majority of homozy-
gous Fat4–deficient embryos (30 of 45 across 27 litters) exhibited 
subcutaneous edema (Figure 2D, arrow), suggestive of a lymphatic 
vascular defect. Whole-mount immunostaining of embryonic dor-
sal skin demonstrated a striking increase in lymphatic vessel width 
in E14.5 Fat4Δ/Δ embryos compared with lymphatic vessel widths 
in littermate controls (Figure 2, B, C, and E), coupled with a signifi-
cant reduction in the number of lymphatic vessel branches (Figure 
2F). No substantial changes in the caliber or branching of the der-
mal blood vascular network were observed (Supplemental Figure 
1; supplemental material available online with this article; https://
doi.org/10.1172/JCI99027DS1). We next investigated lymphatic 
vessel morphology at E18.5, a stage at which valve development 
has been initiated in the collecting lymphatic vessels of the mouse 
and heart (30). The appropriate allocation of cell polarity is a crucial 
determinant of ordered tissue architecture. Establishment of cell 
polarity within the vasculature is imperative both for the coordi-
nated response of endothelial cells to sprouting and guidance cues 
that orchestrate vascular growth and for the specification of lumi-
nal and abluminal identity required to mediate vessel perfusion 
and endothelial cell barrier function. FAT4 has been demonstrated 
to coordinate cell polarity via interactions with its ligand, the large, 
atypical cadherin Dachsous1 (DCHS1) (31), a homolog of Drosoph-
ila Dachsous (23), and also genetically interacts with members of 
the “core” PCP pathway including VANGL planar cell polarity 2) 
(25). Intriguingly, Vangl2 and an additional core PCP component 
cadherin, EGF LAG seven-pass G-type receptor 1 (Celsr1) are both 
important for mediating the junctional remodeling and changes in 
cell orientation required for lymphatic vessel valve morphogenesis 
(32), and a mutation in CELSR1 was recently reported in hereditary 
lymphedema (33). Although less is known regarding the mecha-
nisms by which FAT4 regulates mammalian Hippo pathway activi-
ty, FAT4 has been suggested to restrict access of the key transcrip-
tional Hippo pathway effector yes-associated protein (YAP) to the 
nucleus, such that loss of Fat4 function facilitates the nuclear entry 
of YAP, resulting in elevated cell proliferation (28–30).
In a search for target genes of GATA binding protein 2 
(GATA2), a key regulator of lymphatic vessel morphogenesis and 
valve development, in primary embryonic mouse LECs (mLECs), 
we identified Fat4 and Dchs1. Both genes were significantly 
reduced in expression following GATA2 knockdown in primary 
embryonic mLECs. Here, we describe a crucial cell-autonomous 
role for Fat4 in the control of LEC polarity during lymphatic vas-
cular development. Our data reveal important roles for Fat4 in the 
regulation of polarity during lymphatic vessel morphogenesis and 
provide insight into the mechanisms by which loss-of-function 
mutations in FAT4 cause Hennekam syndrome.
Results
Fat4 and Dchs1 are GATA2 target genes in LECs. To identify genes 
regulated by the pivotal transcriptional regulator of lymphatic 
vessel valve morphogenesis, GATA2, we undertook gene profil-
ing of control and Gata2 siRNA–treated primary mouse embry-
Figure 1. FAT4 and DCHS1 are GATA2 target 
genes. (A) GATA2-deficient hLECs had reduced 
expression of FAT4 and DCHS1 mRNA. (B) West-
ern blots probed with FAT4 and β-actin revealed 
decreased FAT4 protein levels in hLECs treated 
with GATA2 siRNA (siGATA2). (C) Quantification 
of FAT4 levels following GATA2 knockdown. 
siCont., control siRNA. (D) ChIP-Seq profile 
demonstrating GATA2 occupancy (red arrows) in 
the first intron of FAT4 in hLECs. Data indicate 
the mean ± SEM (A) or ± SD (C). n = 3. *P < 0.05 
and **P < 0.01 by 2-tailed Student’s t test.
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ally observed in Fat4ΔLEC embryos at E14.5 (Figure 3D). 
Together, these data suggested that potentially addition-
al, non–LEC-autonomous roles of Fat4 might contribute 
to the branching and edema phenotypes that are a fea-
ture of Fat4Δ/Δ embryos. To investigate this possibility, we 
documented the expression of Fat4 with respect to the 
embryonic lymphatic vasculature using RNA ISH. These 
analyses revealed prominent Fat4 expression in the 
mesenchyme surrounding lymphatic vessels, as well as 
in the heart, particularly in cardiac valves, (Supplemen-
tal Figure 3), where both Dchs1 and Fat4 play important 
morphogenetic roles (31, 37, 38). Mesenchymal FAT4 
could potentially affect branching of the dermal lym-
phatic vasculature, either via homotypic interaction with 
FAT4 in LECs, or heterotypic interaction with DCHS1 in LECs, 
whereas cardiac defects are commonly reported to cause edema. 
Together, these expression data provide potential mechanisms to 
explain the presence of the branching and edema phenotypes in 
Fat4Δ/Δ but not Fat4ΔLEC embryos.
We next analyzed mesenteric lymphatic vessel valve develop-
ment in Fat4ΔLEC embryos at E18.5, following the administration of 
tamoxifen at E12.5, 13.5, and 14.5 (Figure 3, H–M). Whole-mount 
immunostaining of mesenteric collecting lymphatic vessels 
revealed that, like Fat4Δ/Δ embryos, the number of PROX1hi lym-
phatic vessel valve territories was significantly reduced in Fat4ΔLEC 
embryos compared with that observed in the control counterparts 
(Figure 3, H, J, and K). As in Fat4Δ/Δ embryos, lymphatic vessel 
valves also appeared less mature in Fat4ΔLEC mice, reflected by 
greatly reduced laminin α5 levels in prospective valve territo-
ries of mutants compared with levels in controls (Figure 3, I and 
L). These data demonstrate that Fat4 regulates lymphatic vessel 
growth and morphogenesis, and in particular valve development, 
in a LEC-autonomous manner.
Fat4 controls LEC polarity. In considering the mechanisms 
underlying the dramatic lymphatic vascular phenotypes observed 
in Fat4-deficient embryos, we assessed the integrity of 2 pathways 
regulated by Fat4 in a tissue-specific context: cell polarity (25–27) 
and Hippo (28–30) pathway activity. Given the similarity of the der-
mesentery. We observed a significant reduction in the number of 
lymphatic vessel valves, indicated by clusters of PROX1hi cells, in 
Fat4Δ/Δ embryos compared with their control counterparts (Figure 
2, G, I, and J). Moreover, immunostaining for laminin α5, a marker 
reflective of lymphatic vessel valve maturation (35), indicated that 
the valves that had initiated development were substantially less 
mature in Fat4Δ/Δ embryos than were those in control littermates 
(Figure 2, H and K). Analysis of tissue sections revealed profound 
dilation of both dermal and submucosal lymphatic vessels in E18.5 
Fat4Δ/Δ embryos compared with tissue sections from littermate 
controls (Supplemental Figure 2).
A LEC-autonomous requirement for Fat4 in lymphatic vessel 
morphogenesis. To address the LEC-autonomous requirement for 
Fat4 in lymphatic vascular development, we deleted Fat4 in the 
lymphatic vasculature by crossing Fat4fl/fl mice (25) with Prox1-
CreERT2 mice (36). We first analyzed dermal lymphangiogenesis 
at E14.5, following tamoxifen administration to pregnant females 
at E10.5, 11.5, and 12.5 (Figure 3, A–G). As observed in Fat4Δ/Δ 
embryos, the dermal lymphatic vessels of Fat4ΔLEC embryos were 
significantly wider in caliber than were those of their control 
counterparts (Fat4fl/fl) (Figure 3, B, C, and E). Although there was 
a trend toward a reduced number of lymphatic vessel branches 
in Fat4ΔLEC embryos, this decrease was not statistically significant 
(Figure 3F). In addition, subcutaneous edema was not gener-
Figure 2. Fat4Δ/Δ embryos exhibit lymphatic vessel defects. 
E14.5 Fat4Δ/Δ embryos exhibit subcutaneous edema (arrow, 
D) not evident in the littermate controls (A). Whole-mount 
immunostaining of the dorsal skin sprouting front revealed that 
dermal lymphatic vessels, stained with PROX1 (red) and NRP2 
(cyan), were wider (B, C, and E) and less branched (B, E, and F) in 
E14.5 Fat4Δ/Δ embryos (Δ/Δ) compared with littermate controls. 
Whole-mount immunostaining of E18.5 mesenteries with 
PROX1 (red) demonstrated reduced numbers of PROX1hi valves 
(per millimeter of spoke length) in Fat4Δ/Δ mesenteric lymphatic 
vessels (G, J, and I). Fat4Δ/Δ mesenteric lymphatic valve–form-
ing cells (FOXC2hi cells, green) failed to polarize and had less 
laminin-α5 (LAMA5, red) than did littermate controls (H and K). 
Data indicate the mean ± SEM. n = 8 control embryos and n = 11 
Δ/Δ embryos (7 independent E14.5 litters) (C and F); n = 3 control 
embryos and n = 7 Fat4Δ/Δ embryos (3 independent E18.5 litters) 
(I). *P < 0.05 and ***P < 0.0001, by 2-tailed Student’s t test. 
Scale bars: 2.5 mm (A and D), 100 μm (B and E), 500 μm (G and 
J), and 25 μm (H and K). Cont., control.
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phatic endothelial progenitor cells upon their exit from the 
cardinal veins at E11.5. Whole-mount immunostaining of 
E11.5 embryos and measurement of the nuclear length/
width ratio in LECs migrating away from the cardinal veins 
revealed that LEC nuclei were significantly less elliptical 
and therefore less polarized in Fat4Δ/Δ embryos compared 
with littermate controls (Figure 4, J–N), demonstrating 
that polarity was disrupted from the onset of lymphangio-
genesis in the embryo.
Alterations in cell polarity are also important for the 
cellular rearrangements and collective cell migration 
crucial for the formation of valve leaflets during lymphat-
ic vessel valve morphogenesis (32). For this reason, we 
assessed LEC polarity in prospective valve endothelial cells 
of the mesenteric collecting lymphatic vessels at E18.5. As 
observed in actively sprouting and migrating lymphatic 
vessels, the nuclear ellipticity of valve endothelial cells was 
significantly reduced in Fat4Δ/Δ embryos (Figure 4, O–Q), demon-
strating their failure to polarize appropriately. Together, these data 
demonstrate that Fat4 is an important regulator of LEC polarity, 
both in cells within actively sprouting vessels and in cells within 
developing valves. Defective polarity would be predicted to result 
in the increase in lymphatic vessel width observed in the skin of 
Fat4-deficient mice at E14.5; instead of endothelial cells dividing 
in a polarized fashion to extend the length of vessels, nonorient-
ed cell division would result in random distribution of dividing 
cells and increased vessel width. To determine whether defective 
cell polarity arises because of a LEC-autonomous requirement 
for Fat4, we quantified nuclear ellipticity in the dermal lymphatic 
vasculature of E14.5 control and Fat4ΔLEC embryos. These analyses 
revealed significantly reduced nuclear ellipticity and aberrant cell 
polarity in Fat4ΔLEC lymphatic vessels, confirming that FAT4 within 
LECs is responsible for coordinating polarity (Supplemental Fig-
ure 4). Consistent with our observations in the lymphatic vascula-
ture, Fat4 has previously been demonstrated to be required for the 
mal lymphatic vascular phenotype of Fat4-deficient mice to that of 
Pkd1-mutant mice, which exhibit striking defects in cell polarity 
(39), we first investigated polarity within the lymphatic vascula-
ture of Fat4Δ/Δ embryos. We used 2 measures to assess cell polarity: 
Golgi position in sprouting dermal lymphatic vessels and nuclear 
ellipticity. We found that the Golgi, usually positioned ahead of 
the nucleus in the direction of dermal lymphatic vessel sprouting 
toward the embryonic midline (39), was more randomly positioned 
in E14.5 Fat4Δ/Δ mice compared with their control counterparts (Fig-
ure 4, A–D). Likewise, nuclear morphology and overall cell shape, 
normally elliptical in actively migrating cells and more rounded in 
static cells (39), were altered in E14.5 Fat4 mutants; cells were more 
rounded (Figure 4, E–H) and nuclei less elliptical (measured by the 
nuclear length/width ratio) in Fat4Δ/Δ mice compared with control 
mice (Figure 4I). Both of these measures indicated that the polarity 
of Fat4-deficient LECs was aberrant. To determine whether altered 
LEC polarity was a feature of Fat4Δ/Δ embryos from the onset of 
lymphatic vascular development, we examined the polarity of lym-
Figure 3. LEC-autonomous requirement for Fat4 in lymphatic 
vessel morphogenesis. Prox1-CreERT2 Fat4fl/fl male mice were 
crossed with Fat4fl/fl females, and tamoxifen (20 mg/mL, red 
arrows) was administered to pregnant females intraperitoneally at 
10.5, 11.5, and 12.5 days postcoitum (dpc) (G), or 12.5, 13.5, and 14.5 
dpc (M). Embryos were analyzed at E14.5 (A–F) and E18.5 (H–L). 
E14.5 Fat4ΔLEC embryos appeared phenotypically normal (A and D). 
Whole-mount immunostaining of the dorsal skin sprouting front 
revealed that the dermal lymphatic vessels, stained with PROX1 
(red) and NRP2 (cyan), were wider in caliber (B, C, and E) in E14.5 
Fat4ΔLEC embryos compared with littermate control embryos. No 
significant difference was observed in vessel branch points (B, 
E, and F). Whole-mount immunostaining of E18.5 mesenteries 
with PROX1 (cyan) revealed reduced numbers of PROX1hi valves 
in Fat4ΔLEC mesenteric lymphatic vessels (H, J, and K). Fat4ΔLEC 
mesenteric lymphatic valve–forming cells (PROX1hi cells, cyan) 
failed to polarize and had less laminin-α5 (LAMA5, red) than did 
the control counterparts (I and L). Data indicate the mean ± SEM. 
n = 5 control embryos and n = 8 Fat4ΔLEC embryos (3 independent 
E14.5 litters) (C and F); n = 4 control embryos and n = 5 Fat4ΔLEC 
embryos (4 independent E18.5 litters) (J). **P < 0.01, by 2-tailed 
Student’s t test. Scale bars: 2.5 mm (A and D), 100 μm (B and E), 
250 μm (H and K), and 25 μm (I and L). Tam, tamoxifen.
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LEC surface marker neuropilin 2 (NRP2). These analyses revealed 
no significant difference in the number of mitotic LECs relative to 
vessel area in Fat4Δ/Δ embryos compared with littermate controls 
(Supplemental Figure 5, A–C). We next investigated Hippo path-
way activity in primary hLECs in vitro following siRNA-mediated 
FAT4 knockdown. FAT4 siRNA–mediated knockdown of FAT4 in 
hLECs was efficient (Supplemental Figure 6, A and B), resulting 
in undetectable FAT4 protein levels 48 hours after treatment. In 
selected tissue contexts, loss of Fat4 function has been suggest-
oriented cell division important for kidney tubule elongation and 
cochlear extension during development (25).
Analysis of Hippo pathway activity in Fat4-deficient cells. To 
determine whether alterations in Hippo pathway activity might 
also contribute to the lymphatic vascular defects observed in 
Fat4-deficient mice, we first assessed cell proliferation in the 
lymphatic vasculature of E14.5 Fat4Δ/Δ embryos. To this end, we 
performed immunostaining of E14.5 dorsal skin with antibodies 
against the mitotic marker phospho–histone H3 (PH3) and the 
Figure 4. LEC polarity is impaired in Fat4Δ/Δ 
embryos. Whole-mount immunostaining of the 
sprouting front in E14.5 dorsal skins stained for 
PROX1 (red) and GOLPH4 or VE-cadherin (green) 
revealed that Fat4Δ/Δ LECs were more rounded 
(A, B, E, and F), with reduced nuclear ellipticity 
compared with littermate control LECs (I). Repre-
sentative cell shape schematics (G and H), based 
on the corresponding vessels in E and F, highlight 
abnormal LEC elongation axes (red double-headed 
arrows) with respect to the direction of vessel 
migration (black arrows) in Fat4Δ/Δ embryos. 
Reduced nuclear ellipticity was also observed 
in Fat4Δ/Δ LECs (PROX1, red) sprouting from the 
cardinal vein at E11.5 (J–N) and PROX1hi valve–
forming cells in the mesentery at E18.5 (O–Q). 
Boxed regions in J and K reflect the location of the 
cells shown in L and M. Boxed regions in L and M 
are shown at higher magnification in the insets. 
GOLPH4 (green, A and B) staining highlighting 
the Golgi (green, C), normally located ahead of 
the nucleus (red, C) in a 120° arc in migrating cells, 
revealed that Fat4Δ/Δ LECs in E14.5 sprouting der-
mal lymphatic vessels (outlined with the dashed 
gray line) had reduced forward positioning of the 
Golgi (B, arrowheads, and D). Data indicate the 
mean ± SD (D) or the mean ± SEM (I, N, and Q).  
n = 3 control embryos and n = 4 Fat4Δ/Δ embryos (4 
independent E14.5 litters) (D and I); n = 4 control 
embryos and n = 4 Fat4Δ/Δ embryos (3 independent 
E11.5 litters) (N); n = 3 control embryos and n = 7 
Fat4Δ/Δ embryos (3 independent E18.5 litters) (Q). 
*P < 0.05 and **P < 0.01, by 2-tailed Student’s t 
test. Scale bars: 1 mm (J and K), 25 μm (A, B, E, F, 
L, M, O, and P).
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ed to facilitate the nuclear entry of YAP (28–30), enabling YAP 
interaction with transcriptional cofactors including TEA domain 
(TEAD) family members and subsequent induction of Hippo path-
way target genes including ankyrin repeat domain 1 (ANKRD1), 
cellular communication network factor 1 (CCN1, also known as 
CYR61) (40), and CCN2 (4), culminating in cell proliferation. In 
experiments performed in primary hLECs isolated from 3 inde-
pendent donors and cultured in complete media, we observed no 
significant changes in ANKRD1 or CCN1 levels in FAT4-deficient 
cells. Although CTGF levels were reduced (Supplemental Figure 
6C), together these data suggest that there was no major impact 
on Hippo pathway activity as a result of reduced FAT4 levels. We 
next assessed Hippo pathway activity in control and FAT4-defi-
cient primary hLECs in response to VEGF-C. To this end, the ratio 
of cytoplasmic phosphorylated YAP (p-YAP) compared with total 
YAP was quantified across a time course of VEGF-C treatment in 
control and FAT4 siRNA–treated hLECs. No significant changes in 
the p-YAP/YAP ratio were observed in hLECs following VEGF-C 
treatment for up to 60 minutes, suggesting that YAP is not dephos-
phorylated and translocated to the nucleus to activate proliferation 
in response to VEGF-C. Correspondingly, we observed no differ-
ences in the p-YAP/YAP ratio between control and FAT4-deficient 
cells following VEGF-C treatment (Supplemental Figure 6, D and 
E). Concordant with these data, VEGF-C was not a major prolif-
erative stimulus for hLECs, and there was no difference in the 
proliferation of FAT4 siRNA–treated versus control siRNA–treat-
ed hLECs stimulated with VEGF-C (Supplemental Figure 7A). 
Together, these data strongly suggest that the primary mechanism 
underlying the increased lymphatic vessel caliber in Fat4-defi-
cient mice is defective cell polarity.
FAT4 controls LEC polarity in response to flow. To further inves-
tigate the nature of the defective polarity observed in Fat4-defi-
cient LECs in vivo, we first assessed the localization of FAT4 in 
primary hLECs cultured in vitro, both in static conditions and 
following exposure to laminar flow, a stimulus that promotes LEC 
elongation in the direction of flow (42). In static conditions, FAT4 
was observed in a uniformly distributed, punctate pattern at cell-
cell junctions (Figure 5, A–D, and Supplemental Figure 8). Intrigu-
ingly, we found that FAT4 was redistributed in a polarized pattern 
following the exposure of hLECs to laminar flow (Figure 5, E–H). 
We next assessed whether flow-induced changes in hLEC polar-
ity were dependent on FAT4. In static conditions, we observed 
no substantial differences in the size or shape of FAT4-deficient 
cells compared with their control counterparts (Figure 6, A, C, and 
E–I). In contrast, in response to laminar flow, FAT4-deficient cells 
failed to polarize appropriately and instead remained circular (Fig-
ure 6, B and D–I). Moreover, the surface area of FAT4-deficient 
cells following exposure to flow was significantly increased com-
pared with that of FAT4-deficient cells in static conditions (Figure 
6, C–E), a factor that could potentially contribute to the phenotype 
of enlarged vessels observed in Fat4-deficient mice. These data 
are the first to our knowledge to reveal a role for FAT4 in mech-
anotransduction and demonstrate an important role for FAT4 in 
coordinating LEC polarity in response to flow.
Analysis of VEGF-C–initiated VEGFR3 signaling in FAT4-defi-
cient LECs. To explore the possibility that FAT4 is a component 
of the ADAMTS3/CCBE1/VEGF-C/VEGFR3 signaling axis, 
given that mutations in ADAMTS3, CCBE1, and FAT4 all under-
lie Hennekam syndrome, we investigated whether modulation 
of FAT4 levels affected the processes of VEGF-C cleavage and 
activation or VEGF-C–mediated VEGFR3 signal transduction. 
Toward the first of these goals, we performed coimmunoprecipi-
tation assays to determine whether the large extracellular domain 
(ECD) of FAT4 could be coprecipitated with VEGF-C, CCBE1, 
or ADAMTS3, all of which are secreted proteins. No detectible 
association of the FAT4 ECD with any of these proteins was 
observed (Supplemental Figure 9A). We next assessed wheth-
er the extracellular domain of FAT4 modulates ADAMTS3- and 
CCBE1-mediated proteolytic processing of pro–VEGF-C to fully 
active VEGF-C. These assays revealed that the processing of pro–
VEGF-C to its fully cleaved, bioactive form was not affected by 
the addition of the recombinant FAT4 extracellular domain (Sup-
Figure 5. FAT4 is polarized in the direction of flow in hLECs. Under static 
conditions, FAT4 protein (red, A, C, E, and G; black, B, D, F, and H) was 
localized in a punctate pattern at cell junctions in hLECs (A–D). In response 
to laminar shear stress (LSS) (4 dynes/cm2), FAT4 was redistributed 
(arrowheads) and polarized in the direction of flow (E–H). VE-cadherin 
(cyan) and DAPI (white) demarcate the cell junctions and nuclei, respec-
tively (A, C, E, and G). Scale bars: 25 μm (D and H). Insets depict enlarged 
images of the boxed regions in D and H.
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plemental Figure 9B), suggesting that FAT4 does not influence 
the rate or efficiency of VEGF-C activation.
To investigate the possibility that FAT4 might regulate VEGF-C–
initiated VEGFR3 signal transduction, we first assessed the activity 
of signaling pathways known to be induced in LECs as a conse-
quence of VEGF-C–mediated VEGFR3 activation (14, 43). To this 
end, we quantified VEGF-C–driven phosphorylation of the serine/
threonine kinase AKT and the MAP kinase ERK in Fat4 siRNA– 
treated primary embryonic mLECS and FAT4 siRNA–treated pri-
mary adult hLECs compared with control-treated cells across a 
60-minute time course. We performed the experiments in 3 inde-
pendent batches of embryonic dermal mLECs, each isolated from 
17 to 24 embryos, and in 4 independent batches of hLECs (isolated 
from different donors). Immunoblotting of cell lysates harvested 
before VEGF-C treatment and 15, 30, or 60 minutes after VEGF-C 
treatment revealed that both AKT and ERK phosphorylation were 
significantly elevated in Fat4-deficient mLECs 15 and 30 minutes 
after VEGF-C treatment (Supplemental Figure 10, A–D). Interest-
ingly, adult hLECs showed a trend toward elevated AKT activity 
following VEGF-C treatment (Supplemental Figure 10, E and G) 
compared with control-treated cells, though this difference was 
not statistically significant when data were combined from mul-
tiple experiments performed across 4 independent batches of 
hLECs. In contrast, we observed no substantial differences in ERK 
activity in FAT4-deficient hLECs compared with controls follow-
ing VEGF-C stimulation (Supplemental Figure 10, F and H). When 
we compared the responses of FAT4-deficient hLECs isolated 
from different donors with VEGF-C treatment (Supplemental 
Figure 10, I and J), we noted that 2 donors had significantly ele-
vated AKT activity in FAT4 siRNA–treated cells, whereas 2 did not 
(Supplemental Figure 10I). These data reveal that variation exists 
among donors and highlight the importance of assessing gene 
function across multiple independent batches of cells. Our data 
also demonstrate that Fat4-deficient embryonic mLECs had ele-
vated responses to VEGF-C, possibly reflecting increased sensitiv-
ity of embryonic versus adult LECs to this key signaling pathway.
To assess whether altered VEGFR3 levels, localization, or acti-
vation might underlie the elevated AKT activity observed in the 2 
most responsive batches of FAT4-deficient hLECs, we examined 
total VEGFR3 levels in control siRNA– and FAT4 siRNA–treated 
hLECs before and after VEGF-C treatment. Immunoblotting of 
cell lysates revealed no substantial differences in the total levels 
of VEGFR3 present in FAT4-deficient cells compared with lev-
els in control cells before or after VEGF-C treatment, though, as 
expected, VEGFR3 levels progressively decreased over a time 
course of VEGF-C treatment (Supplemental Figure 11, A and B). 
We next assessed the levels of VEGFR3 present on the cell sur-
face and available to bind VEGF-C in FAT4-deficient compared 
with control-treated hLECs. In this case, flow cytometry using 
an antibody that binds the extracellular domain of VEGFR3 was 
performed to quantify the amount of cell-surface VEGFR3 in con-
trol and FAT4-deficient cells before and after VEGF-C treatment 
Figure 6. FAT4-deficient hLECs fail to polarize in response to laminar shear stress. Under static conditions, control siRNA– and FAT4 siRNA–treated 
hLECs were indistinguishable from one another. In response to LSS (4 dynes/cm2), FAT4 siRNA–treated hLECs became larger and more rounded and failed 
to elongate in the direction of flow (A–I). Representative images using VE-cadherin staining to demarcate the cell outline are shown (A–D). Scale bars: 25 μm. 
Data indicate the mean ± SEM. n = 3. *P < 0.05 and **P < 0.01, by 1-way ANOVA with Tukey’s test for multiple comparisons.
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we observed no difference in the mitotic index of LECs between 
Fat4Δ/Δ embryos and their control counterparts (Supplemental 
Figure 5, A–C). Chemotactic migration toward basal media (EBM-
2, 0.5% FBS), basal media containing VEGF-C (100 ng/mL), and 
complete media was assessed in Transwell assays. Mirroring the 
scenario in Fat4-mutant mice, we observed no differences in 
the migration of FAT4-deficient hLECs compared with control 
hLECs in any of these conditions (Supplemental Figure 7B). We 
next investigated the capacity of FAT4-deficient hLECs to sprout 
in response to basal media, VEGF-C, and complete media in 3D 
spheroid assays. VEGF-C is a prominent sprouting and migration 
stimulus for LECs (12, 44). We observed no significant differenc-
es in the number of sprouts extended in basal media, VEGF-C, 
or complete media (Supplemental Figure 7, C and D) between 
FAT4-deficient and control hLECs, mirroring the lack of differ-
ence in the number of filopodia in the sprouting dermal lymphatic 
vasculature of E14.5 Fat4Δ/Δ and control embryos (Supplemental 
Figure 5, D–F). Intriguingly, FAT4-deficient cells exhibited a trend 
toward increased sprouting in basal media and VEGF-C compared 
with control cells. Though this increased sprouting capacity of 
FAT4-deficient hLECs in vitro potentially reflects the elevated 
levels of VEGF-C–initiated AKT activity observed in these cells, 
we think it unlikely that changes in the magnitude of VEGF-C–
initiated signaling contributed significantly to the lymphatic phe-
notype of Fat4Δ/Δ mice, given that we did not observe changes in 
lymphatic vessel sprouting or proliferation in vivo.
Discussion
Here, we identify a crucial, LEC-autonomous role for the atypical 
cadherin FAT4 during lymphatic vessel morphogenesis, revealing 
that FAT4 orchestrates lymphangiogenesis primarily by regulating 
LEC polarity. We demonstrate that Fat4 is required to coordinate 
LEC polarity from the initiation of lymphangiogenesis in the mouse 
embryo and that defects in LEC polarity result in the aberrant mor-
phology and disrupted valve development that are characteristic 
of the lymphatic vasculature in Fat4-mutant embryos. In addition 
to defective polarity, FAT4-deficient embryonic mLECs exhibited 
elevated AKT and ERK activity downstream of VEGF-C–induced 
VEGFR3 phosphorylation in vitro. Though we believe the degree 
to which this role of FAT4 contributes to the lymphatic vascular 
phenotype of Fat4-deficient mice is probably minimal, our data 
provide a potential link between FAT4 and the VEGFR3 signaling 
pathway, suggesting a mechanism by which mutations in FAT4, 
CCBE1, and ADAMTS3 underlie Hennekam syndrome.
Previous analyses of Fat4-null mice demonstrated that FAT4 
regulates PCP in tissues including the kidney, neural tube, inner 
ear, and skeletal tissue (25–27), whereas defects in neural and 
nephron progenitor cells and cardiomyocytes have been attribut-
ed to aberrant Hippo pathway activity as a result of Fat4 loss of 
function (28–30). Our data suggest that in the lymphatic endothe-
lium, Fat4 functions predominantly via regulation of LEC polarity 
rather than Hippo pathway activity. PCP in both invertebrates and 
vertebrates is regulated via 2 major pathways: the “core” pathway 
consisting of frizzled, dishevelled, Diego, Van Gogh, prickle, and 
flamingo components in Drosophila (FZD3, -6; DVL1, -2, -3; VAN-
GL2; Prickle1, -2; and CELSR1, -2, -3 in mammals) and the FAT/
Dachsous pathway consisting of FAT, Dachsous, and Four-jointed 
(Supplemental Figure 11C). We observed no significant differenc-
es in cell-surface VEGFR3 levels between FAT4-deficient and 
control-treated cells and, in both cases, VEGFR3 appeared to be 
internalized following VEGF-C binding, suggesting that the ini-
tial phases of signal transduction were not affected as a result of 
FAT4 deficiency (Supplemental Figure 11C). To investigate the 
activation status of VEGFR3 following VEGF-C treatment, we 
assessed VEGFR3 phosphorylation following 15 minutes of treat-
ment with VEGF-C by immunoprecipitating VEGFR3 and then 
immunoblotting the precipitated receptor with a pan-phosphoty-
rosine antibody. These experiments revealed that consistently 
more VEGFR3 could be immunoprecipitated from FAT4-deficient 
cells than from control cells (Supplemental Figure 11D). Likewise, 
elevated levels of tyrosine-phosphorylated VEGFR3 were detect-
ed in FAT4-deficient cells compared with levels in control cells 
(Supplemental Figure 11D). Intriguingly, although more VEGFR3 
was immunoprecipitated in FAT4-deficient cells, the ratio of tyro-
sine-phosphorylated VEGFR3 to total VEGFR3 immunoprecip-
itated was not significantly altered between FAT4-deficient and 
control cells (Supplemental Figure 11E), suggesting that FAT4 
deficiency does not impact initial VEGFR3 activation.
The intracellular domain of FAT4 interacts with VEGFR3. In 
considering mechanisms by which FAT4 deficiency might regu-
late AKT and ERK activity downstream of VEGFR3 activation, we 
reasoned that a physical interaction between FAT4 and VEGFR3 
could potentially influence the downstream signaling of VEGFR3 
following receptor internalization. To investigate this further, 
we performed coimmunoprecipitation assays to assess whether 
VEGFR3 could associate with the intracellular domain (ICD) of 
FAT4 when ectopically expressed in human embryonic kidney 
293 (HEK293) cells. Immunoblotting of the immunoprecipitated 
FAT4 ICD revealed a robust interaction between the FAT4 ICD 
and VEGFR3, both in the absence and presence of VEGF-C (Sup-
plemental Figure 11F). Control experiments confirmed the speci-
ficity of immunoprecipitations (Supplemental Figure 11G). These 
data demonstrate that FAT4 and VEGFR3 have the capacity to 
physically associate and, therefore, that FAT4 has the potential to 
regulate signal transduction downstream of VEGFR3 activation. 
Moreover, this interaction might explain why more VEGFR3 could 
be immunoprecipitated from FAT4-deficient cells, should VEG-
FR3 be more accessible to the antibody used for VEGFR3 pull-
down in the absence of FAT4.
FAT4 regulation of LEC responses to VEGF-C. To investigate 
the biological impact that elevated, VEGF-C–initiated signaling 
might have on FAT4-deficient LECs, we assessed the responses 
of FAT4-deficient primary hLECs to both VEGF-C and complete 
media, using established proliferation, sprouting, and migration 
assays. All experiments were performed in at least 3 independent 
batches of hLECs (isolated from different donors). In the case of 
proliferation, which we have previously shown is not primarily 
driven by VEGF-C (44), we observed no significant differences 
between control and FAT4 siRNA–treated hLECs grown for 48 
hours in basal media (Endothelial Cell Basal Medium 2 [EBM-2], 
2% FBS), basal media containing VEGF-C (100 ng/mL), or Micro-
vascular Endothelial Cell Growth Medium-2 SingleQuots com-
plete media (EGM-2MV) (Supplemental Figure 7A). These data 
are consistent with our analyses of proliferation in vivo, in which 
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sequences of FAT4 mutations found in Hennekam syndrome for 
both LEC polarity and VEGF-C initiated signaling via VEGFR3.
Why does loss of FAT4 function not have the same impact 
as loss of CCBE1 or ADAMTS3 function on VEGF-C/VEGFR3 
signal transduction, given that mutations in all 3 genes underlie 
Hennekam syndrome? Lymphangiectasia, presenting as dilation 
of lymphatic vessels and often associated with lymphedema (52), 
is not only a feature of Hennekam syndrome but has been report-
ed in human lymphatic dysplasia syndromes including Noonan 
syndrome (53), caused by hyperactivation of the RAS/MAPK sig-
naling pathway and excessive lymphangiogenesis (54). It is like-
ly that mechanisms including defective LEC polarity, defective 
valve development, and hyperplasia of the lymphatic vasculature 
all result in lymphangiectasia. The lymphangiectasia reported 
in patients with Hennekam syndrome is a prominent feature of 
Fat4-null mice and is probably caused by defective cell polarity. 
Of interest, Fat4 deletion in mice results in a less-severe lymphatic 
phenotype than does deletion of either Ccbe1 or Adamts3, both of 
which essentially mirror Vegfc loss of function. In the patients with 
Hennekam syndrome studied to date, the onset of lymphedema in 
patients with CCBE1 has been reported from birth, whereas lymph 
edema can occur at a later point in Hennekam syndrome caused 
by FAT4 mutations, suggesting that CCBE1 mutations are more 
deleterious with respect to their effect on embryonic lymphangio-
genesis. It is also possible that in Hennekam syndrome, yet-to-be-
described phenotypic differences exist that are caused by CCBE1, 
ADAMTS3, and FAT4 mutations. Intriguingly, lymphedema has 
been reported in only 1 patient with Van Maldergem syndrome to 
date (55). Van Maldergem syndrome shares features of Hennekam 
syndrome, including periventricular neuronal heterotopia, and is 
caused by mutations in FAT4 or DCHS1 (29). The report of only 
1 patient with a DCHS1 mutation who had obvious lymphedema 
(55) suggests that DCHS1 mutations are yet to be identified in 
Hennekam syndrome or, alternatively, that mutations in addition-
al components of the FAT4/DCHS1 pathway may also underlie 
Hennekam syndrome. Variation in patient phenotype has been 
reported even between patients carrying the same GATA2 muta-
tion, which causes lymphedema in some patients and hematologi-
cal or immune dysfunction in others (56).
While this manuscript was in preparation, a brief report was 
published describing a requirement for Fat4 and Dchs1 in lymphat-
ic vessel valve morphogenesis (38). This study concurs with ours 
in documenting a role for Fat4 in the control of LEC polarity that 
is important for valve development, but did not dissect the LEC- 
autonomous requirement for these proteins or describe their roles 
in earlier phases of lymphangiogenesis before valve development. 
Our study is also the first to our knowledge to document a potential 
link between FAT4 and the VEGF-C/VEGFR3 signaling pathway.
In conclusion, we document a crucial, LEC-autonomous 
role for Fat4 in the control of LEC polarity. We demonstrate that 
orchestration of polarity is crucial for building functional lymphat-
ic vessels; disruption of LEC polarity due to Fat4 loss of function 
results in aberrant lymphatic vessel morphology and defective 
lymphatic vessel valve morphogenesis. We also provide the first 
evidence, to our knowledge, demonstrating that FAT4 is import-
ant for mechanotransduction and, in particular, for transducing 
flow-induced signals in LECs. It will be fascinating to further 
in Drosophila (FAT4/DCHS1/FJX1 in mammals) (45). The mech-
anisms by which FAT4 transmits signals to downstream compo-
nents of the cell polarity machinery to mediate cell polarization 
are not completely understood, but genetic interactions between 
FAT4 and components of both the FAT/Ds (FAT1) and core path-
ways (VANGL2) have been documented (25, 46, 47). The recent 
demonstration of a requirement for both Celsr1 and Vangl2 in lym-
phatic vessel valve morphogenesis (32) suggests the intriguing 
possibility that FAT4 might cooperate with these core PCP pro-
teins to coordinate valve endothelial cell polarity. Further dissec-
tion of the molecular mechanisms via which Fat4 coordinates LEC 
polarity will be explored in future work.
How do the FAT4 mutations found in Hennekam syndrome 
impact FAT4 function? Though we have demonstrated here that 
Fat4 is crucial to coordinate LEC polarity during lymphatic vessel 
morphogenesis in vivo and in response to flow in vitro, the mecha-
nisms by which Hennekam syndrome mutations alter FAT4 activ-
ity to cause lymphatic vascular dysfunction remain to be estab-
lished. To date, the homozygous and compound heterozygous 
mutations reported in Hennekam syndrome are largely missense 
mutations located in the cadherin repeats of the extracellular 
domain of FAT4 that are predicted to be deleterious by SIFT and 
PolyPhen algorithms (21). To further explore the potential conse-
quences of Hennekam syndrome mutations on FAT4 structure 
in silico, we substituted Hennekam syndrome mutations into the 
corresponding, highly conserved regions of the E-cadherin ect-
odomain, for which high-resolution crystal structures have been 
established (48). Hennekam syndrome mutations Phe475Leu, 
Glu486Gln, and Glu2375Lys, all of which result in changes to res-
idues highly conserved between FAT4 and E-cadherin, revealed 
that these mutations would be predicted to disrupt calcium coor-
dination (48), a crucial factor in cadherin function. Previous work 
from Tsukasaki and colleagues reported that the huge extracel-
lular domains of FAT4 and DCHS1 adopt a structure compatible 
with the confines of intercellular spaces due to their substitution 
of amino acids in the linker regions between cadherin repeats 
responsible for calcium binding (49). Loss of calcium binding 
capacity resulted in the adoption of sharp, hairpin-like bends, 
predicted to enable FAT4 and DCHS1 to adopt a compact spatial 
organization (49). On the basis of this work, the disruption of cal-
cium-coordinating residues due to Hennekam syndrome muta-
tions might be expected to result in hairpin-like bends that could 
have severe consequences on the structure of the FAT4 extracel-
lular domain, potentially affecting the binding of FAT4 to DCHS1 
and/or other ligands or coreceptors. Alternatively, Hennekam 
mutations might affect the ability of FAT4 to transduce flow- or 
shear-induced signal transduction. VEGFR3 is a key component 
of the VEGFR2–VEGFR3–VE-cadherin mechanosensory complex 
in endothelial cells and is important for coordinating changes 
in cell orientation that occur in response to shear stress (50, 51). 
Our identification of an interaction between VEGFR3 and FAT4 
raises the possibility that FAT4 might also regulate the capaci-
ty of VEGFR3 to transduce flow-mediated signals. Although our 
data demonstrate a link between FAT4 and the VEGF-C/VEGFR3 
pathway in primary LECs in vitro, we believe that the lymphatic 
vascular defects observed in Fat4Δ/Δ mice are largely explained by 
defective LEC polarity. It will be intriguing to investigate the con-
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were immunostained as previously described (59). Images were cap-
tured at RT using either a Carl Zeiss LSM 700 Axio Observer Z1 confo-
cal microscope equipped with 405 nm, 488 nm, 555 nm, and 639 nm 
lasers, or a Carl Zeiss LSM 800 Axio Observer 7 confocal microscope 
with Airyscan, equipped with 405 nm, 488 nm, 561 nm, and 640 nm 
lasers. Images were compiled using ZEN 2.5 (blue edition; Zeiss) and 
Adobe Photoshop CC (version 20.0.1) software.
Quantification of lymphatic vessel parameters. All lymphatic vessel 
parameters were quantified in at least 3 embryos per genotype across 
a minimum of 3 independent litters. The sample number for each 
experiment is specified in the figure legends. Dermal lymphatic vessel 
width (μm) and branch points were quantified within 1.28 mm of the 
sprouting front on both sides of the dorsal midline using ImageJ (NIH) 
(60) as previously described (59). The number of mesenteric lymphat-
ic vessel valves was counted along 5 to 12 spokes per mesentery and 
normalized to the spoke length (mm), measured using ImageJ (60).
PH3-positive LECs were counted in dermal lymphatic vessels with-
in 640 μm of the sprouting front on both sides of the dorsal midline (3 
images from each side of the midline, totaling 6 images per embryo) and 
normalized to the lymphatic vessel area (mm2), measured using ImageJ 
(60). Filopodial counts were performed using the same 6 images and 
normalized to the 100-μm lymphatic vessel length at the sprouting front.
The Golgi position in relation to nuclei was scored (either within or 
outside the 120° frontal arc) in cells within 160 μm of the sprouting front 
on both sides of the dorsal midline. Six fields of view (FOV) per E14.5 
embryo were counted, equating to 50–70 nuclei. To determine nucle-
ar ellipticity (ratio of nuclear length/width), nuclear width and length 
were measured using ImageJ (60). For E11.5 analyses, 50–80 nuclei per 
embryo were measured, for E14.5 analyses 40–130 nuclei per embryo 
were measured, and for E18.5 analyses, nuclei were measured in 20–50 
PROX1hiFOXC2hi valve-forming endothelial cells per mesentery.
Cell culture. Primary adult human dermal microvascular LECs 
(HMVEC-dLyAd) were purchased from Lonza and are referred to 
here as hLECs. All in vitro experiments were performed in at least 3 
independent batches of hLECs (isolated from different donors; lot 
numbers 7F3304, 0000254463, 4F3029, and 4F3037). Recombinant 
VEGF-C from R&D Systems (2179-VC-025) or ReliaTech (R20-015) 
was used for assays. Primary embryonic mLECs (mLECs) were isolat-
ed from E16.5 mouse dermis as previously described (44). hLECs and 
mLECs were cultured in EBM-2 (Lonza) supplemented with EGM-
2MV (Lonza). HEK293 cells (a gift from Stuart Pitson, Centre for Can-
cer Biology, Adelaide, Australia) were maintained in DMEM with high 
glucose containing 10% FBS.
Transfection. mLECs were transfected using Lipofectamine RNAi-
MAX Transfection Reagent (Invitrogen, Thermo Fisher Scientific) 
according to the manufacturer’s instructions 24 and 48 hours after seed-
ing using FAT4 Silencer Select Predesigned siRNA (s116449; Thermo 
Fisher Scientific). hLECs were transfected using Lipofectamine RNAi-
MAX or Lipofectamine 2000 Transfection Reagent (Invitrogen, Ther-
mo Fisher Scientific) according to the manufacturer’s instructions and 
with FAT4 Silencer Select Predesigned siRNA (s35967; Thermo Fisher 
Scientific), FAT4 MISSION esiRNA (EHU069061; MilliporeSigma), 
or GATA2 Silencer Select Predesigned siRNA (s5596; Thermo Fisher 
Scientific). Silencer Select Negative Control No. 1 siRNA (4390844; 
Thermo Fisher Scientific) or EGFP MISSION esiRNA negative control 
(EHUEGFP; MilliporeSigma) was used as a control treatment for the 
respective experiments.
dissect the mechanisms by which FAT4 transduces mechanical 
signals in endothelial cells. Identification of the molecular com-
ponents important for regulating LEC polarity, mechanotrans-
duction, and VEGFR3 signaling via Fat4 will form the basis of our 
future studies, as will further investigation into the mechanisms 
by which Hennekam syndrome mutations impact FAT4 function. 
Answers to these questions will provide important insight into 
how alterations in lymphatic vessel architecture result in human 
lymphatic vascular diseases including Hennekam syndrome.
Methods
Mouse studies. Fat4fl/fl (25), Prox1-CreERT2 (36), and CMV-Cre (34) 
mice have been previously described. All mouse lines were back-
crossed onto a C57BL/6J background. Adult female mice were sub-
jected to timed pregnancies, scored by the presence of vaginal plugs, 
with 9:00 am on the day of plug detection designated 0.5 days post-
coitum. To generate Fat4-null mice, Fat4fl/fl mice were crossed with 
CMV-Cre mice to generate Fat4+/Δ mice, which were crossed to yield 
Fat4Δ/Δ mice. For excision of floxed alleles using Prox1-CreERT2, 20 
mg/mL tamoxifen (MilliporeSigma) was dissolved in peanut oil con-
taining 10% (v/v) ethanol. Pregnant mice were injected intraperito-
neally with 2.5 mg per 25 g body weight at the indicated time points. 
Littermate control embryos were either Fat4+/+ or Fat4fl/fl depending 
on the Cre deleter strain used.
Antibodies. For immunofluorescence staining, the following pri-
mary antibodies were used: goat anti–human PROX1 (AF2727; R&D 
Systems), rat anti–mouse FOXC2 (57), rabbit anti-GOLPH4 (ab28049; 
abcam), rabbit anti–mouse laminin α5 (58), goat anti–human neuro-
pilin 2 (AF2215; R&D Systems), rabbit neuropilin 2 XP (3366; Cell 
Signaling Technology), rat anti-endomucin (V.7C7, sc-65495; Santa 
Cruz Biotechnology), rat anti–mouse CD31 (102502; BioLegend), 
rat anti–mouse CD144 (550548; BD Biosciences), goat anti–mouse 
VE-cadherin (AF1002; R&D Systems), anti–α-smooth muscle actin-
Cy3 antibody (C6198; MilliporeSigma), rabbit anti-FAT4 (HPA052819; 
MilliporeSigma), and rabbit PH3 (Ser10) (06-570; MilliporeSigma). 
Alexa Fluor–conjugated antibodies (Life Technologies, Thermo Fisher 
Scientific) were used for visualization. Rabbit anti-AKT (9272; Cell Sig-
naling Technology), rabbit anti–p-AKT (Thr308) (4056; Cell Signaling 
Technology), rabbit anti–p44/42 MAPK (ERK1/2, 4695; Cell Signaling 
Technology), rabbit anti–p-p44/42 MAPK (Thr202/Tyr204) (4370; 
Cell Signaling Technology), goat anti-FAT4 (P-17, sc-161577; Santa 
Cruz Biotechnology), mouse anti–β-actin (A5441; MilliporeSigma), 
mouse anti–phosphotyrosine (p-Tyr-100, 9411; Cell Signaling Tech-
nology), mouse anti-FLT4 (G-3, sc-365748; Santa Cruz Biotechnology), 
goat anti–mouse VEGFR3 (AF743; R&D Systems), mouse anti-YAP 
(H-9, sc-271134; Santa Cruz Biotechnology), rabbit anti–p-YAP (Ser127) 
(4911; Cell Signaling Technology), normal rabbit IgG (sc-2027; Santa 
Cruz Biotechnology), rabbit anti-GATA2 (H-116X, sc-9008; Santa Cruz 
Biotechnology), mouse anti–V5-HRP (46-0708; Invitrogen, Thermo 
Fisher Scientific), mouse anti–FLAG M2-HRP (A8592; MilliporeSig-
ma), mouse anti–HA.11 epitope tag (MMS-101P; BioLegend), and rab-
bit anti–DYKDDDDK tag antibody (2368; Cell Signaling Technology) 
were used for immunoblotting and immunoprecipitation experiments.
Immunostaining. For cryopreserved sections and whole-mount 
staining of skin, embryos were fixed in 4% paraformaldehyde (PFA) 
overnight at 4°C. Mesenteries were fixed in 4% PFA for 10 minutes or 
1 hour at room temperature (RT). Whole-mount tissues and sections 
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plemented with 0.5% FBS, and stimulated with 100 ng/mL VEGF-C 
for 15 minutes. Cells were harvested in ice-cold PBS and collected by 
centrifugation (200 × g for 10 minutes at 4°C). Cell pellets were lysed 
in lysis buffer containing 20 mM Tris, pH 7.5, 150 mM NaCl, and 1% 
IGEPAL CA-630 (MilliporeSigma) supplemented with Halt Prote-
ase and Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific). 
Lysates were sonicated and centrifuged, and the protein concentra-
tions were estimated using a BCA Protein Assay Kit (Pierce, Thermo 
Fisher Scientific) according to the manufacturer’s instructions. To 
immunoprecipitate VEGFR3, 125 μg of the respective cell lysate was 
incubated with 1.25 μg mouse anti-Flt4 (G-3, sc-365748; Santa Cruz 
Biotechnology) and antibody-antigen complexes were precipitated 
with Dynabeads Protein G (Life Technologies, Thermo Fisher Scien-
tific). Immunoprecipitates were washed with lysis buffer, resuspended 
in Laemmli sample buffer, and heated at 95°C for 5 minutes. Immuno-
blotting was performed as detailed above.
To analyze protein interactions via coimmunoprecipitation, 
HEK293 cells were cotransfected with FLAG-tagged FAT4 intracellu-
lar domain (NM_183221, residues 4527–4981) in pCMV6-Entry (Ori-
Gene) and VEGFR3 (NM_182925) in pcDNA3.1(+) expression vector 
(Thermo Fisher Scientific) or empty vector using Lipofectamine 2000 
(Invitrogen, Thermo Fisher Scientific) according to the manufacturer’s 
instructions. Cotransfected cells were lysed in lysis buffer, sonicated, 
and centrifuged. To immunoprecipitate the FAT4 intracellular domain, 
cell lysates prepared from cells ectopically expressing FAT4 intracel-
lular domain and VEGFR3 or empty vector were incubated with rab-
bit anti-DYKDDDDK tag antibody (2368; Cell Signaling Technology) 
or normal rabbit IgG (sc-2027; Santa Cruz Biotechnology), and anti-
body-antigen complexes were precipitated with Dynabeads Protein G 
(Life Technologies, Thermo Fisher Scientific). To immunoprecipitate 
VEGFR3, lysates prepared from cells ectopically expressing FAT4 intra-
cellular domain and VEGFR3 were incubated with goat anti–mouse 
VEGFR3 (AF743; R&D Systems) or control IgG and antibody-antigen 
complexes precipitated with Dynabeads Protein G (Life Technologies, 
Thermo Fisher Scientific). Immunoprecipitates were washed with lysis 
buffer, resuspended in Laemmli sample buffer, and heated at 95°C for 5 
minutes. Immunoblotting was performed as detailed above.
FAT4 cloning and protein expression. The extracellular domain of 
human FAT4 (FAT4-EC) was cloned by amplifying multiple overlapping 
fragments of FAT4 by PCR, using cDNA reverse transcribed from RNA 
harvested from hLECs (Lonza) as a template, and assembled into the 
pCMV6-AC-HA vector (Origene) using NEBuilder HiFi DNA Assembly 
(E2621; New England BioLabs). HEK293T cells were plated at a den-
sity of 3 × 105 cells per 10 cm2, and epitope-tagged cDNA constructs 
were transfected into these cells using FuGENE6 Transfection Reagent 
(E2691; Promega). Unless otherwise indicated, conditioned media were 
collected 72 hours after transfection. Untransfected HEK293T condi-
tioned media were collected and used as control supernatant. Immuno-
blotting was performed using anti–V5-HRP (46-0708; Invitrogen, Ther-
mo Fisher Scientific), anti–FLAG M2-HRP (A8592; MilliporeSigma), 
and anti–HA.11 epitope tag (MMS-101P; BioLegend) antibodies and 
developed with ECL reagent (Thermo Fisher Scientific).
Immunoprecipitation of FAT4 with VEGF-C, CCBE1, ADAMTS3. 
Conditioned supernatants were harvested and mixed for 18 hours at 
4°C before addition of anti–HA-conjugated magnetic beads (11201D; 
Thermo Fisher Scientific and sc-7392; Santa Cruz Biotechnology). 
Beads were washed 3 times using Opti-MEM (Thermo Fisher Scien-
ChIP-Seq analysis. Sheared chromatin from 10 million cell equiv-
alents was immunoprecipitated with 15 μg rabbit anti-GATA2 anti-
body (H-116X, sc-9008; Santa Cruz Biotechnology). ChIP-Seq library 
preparation and sequencing were carried out at the Australian Can-
cer Research Foundation (ACRF) Cancer Genomics Facility, Cen-
tre for Cancer Biology (Adelaide, Australia) as previously described 
(61). ChIP-Seq data have been deposited in the European Nucleotide 
Archive (ENA) under the accession number PRJEB9436 (http://www.
ebi.ac.uk/ena/data/view/PRJEB9436).
RNA analysis. Total RNA was isolated from cells using TRIzol 
(Invitrogen, Thermo Fisher Scientific) according to the manufacturer’s 
instructions. For investigation of mRNA levels, RNA was reverse tran-
scribed using the QuantiTect Reverse Transcription Kit (QIAGEN). 
Real-time RT-PCR was performed in triplicate using RT2 SYBR Green 
ROX qPCR Mastermix (QIAGEN) and run on a Corbett Research 
Rotor-Gene 6000 real-time rotary analyzer (QIAGEN) using the prim-
ers listed in Supplemental Table 1. Data were analyzed using Rotor-
Gene Q Series software (version 2.3.1; QIAGEN). All data were normal-
ized to the housekeeping gene ALAS1, as previously described (62).
ISH. RNA ISH was performed as previously described (63), using 
Fat4 digoxigenin-labeled riboprobes (25). Probes were hybridized to 
cryopreserved E14.5 WT 10-μm sections. Probe specificity was con-
firmed using a corresponding sense probe. Immunostaining for PROX1 
was performed following ISH as previously described (59). Whole 
embryo bright-field scans were captured using 3DHISTECH Pannoram-
ic 250 Flash II. PROX1 costaining was acquired using confocal micros-
copy as detailed above. Images were compiled using ZEN 2.5 (blue edi-
tion; Zeiss) and Adobe Photoshop CC (version 20.0.1) software.
Immunoblotting and immunoprecipitation. To assess endogenous 
FAT4 protein levels, transfected cells were harvested in T-PER Tissue 
Protein Extraction Reagent (Thermo Fisher Scientific) supplement-
ed with Halt Protease and Phosphatase Inhibitor Cocktail (Thermo 
Fisher Scientific). After addition of 4× Laemmli sample buffer (200 
mM Tris, pH 6.8, 400 mM DTT, 8% [w/v] SDS, 40% glycerol, bro-
mophenol blue), protein extracts were heated at 95°C for 3 minutes. 
Samples were resolved by SDS-PAGE (Bio-Rad Criterion XT 3%–8% 
Tris-Acetate Precast Protein Gels), transferred onto PVDF mem-
branes (PerkinElmer), and blotted with respective primary antibodies. 
Immunoblots were visualized using ECF reagent (GE Healthcare) or 
Immun-Star AP substrate (Bio-Rad) on a Typhoon FLA 9000 (GE 
Healthcare) or ChemiDoc MP Imaging system (Bio-Rad) and quanti-
fied using ImageQuant TL 1D (version 8.1; GE Healthcare) or Image 
Lab (Bio-Rad) software.
To assess VEGF-C–initiated signaling and Hippo pathway activ-
ity, transfected cells were serum starved for 16 hours in EBM-2 sup-
plemented with 0.05% AlbuMAX (Gibco, Thermo Fisher Scientific) 
(mLECs) or 0.5% FBS (hLECs) and stimulated with VEGF-C (200 ng/
mL for mLECs or 100 ng/mL for hLECs) for the designated durations. 
Cells were then harvested in 4× Laemmli sample buffer (200 mM Tris, 
pH 6.8, 400 mM DTT, 8% [w/v] SDS, 40% glycerol, bromophenol 
blue) and heated at 95°C for 7 minutes. For immunoblotting, samples 
were resolved by SDS-PAGE (Bio-Rad Mini-PROTEAN TGX Stain-
Free 4%–20% Precast Protein Gels), transferred onto PVDF mem-
branes (PerkinElmer), and blotted with the respective primary anti-
bodies. Immunoblots were visualized as detailed above.
To assess VEGFR3 phosphorylation, hLECs were transfected with 
control or FAT4 siRNA, serum starved for 16 hours with EBM-2 sup-
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cells were dissociated using TrypLE Express Enzyme (Thermo Fish-
er Scientific), pelleted, resuspended in 200 μL ice-cold PBS supple-
mented with 5% FBS, and incubated on ice for 20 minutes. To detect 
VEGFR3, 1 μL APC-conjugated mouse anti–human VEGFR3 antibody 
(FAB3492A, lot LGB0517071; R&D Systems) was added, incubated on 
ice for 20 minutes, and washed by centrifugation (200 × g for 5 min-
utes at 4°C) with 4 mL ice-cold PBS supplemented with 5% FBS. Cells 
were fixed in 2% PFA and analyzed using an LSRFortessa cell analyz-
er (BD Biosciences). Data analysis and visualization were performed 
using FlowJo software (version 10.6.1; BD Biosciences).
Statistics. Unless stated otherwise, P values were calculated using 
the 2-tailed Student’s t test. In vitro flow data were analyzed with 
GraphPad Prism (version 8.0.1; GraphPad Software) using a 1-way 
ANOVA with Tukey’s test for multiple comparisons. P values of less 
than 0.05 were considered statistically significant.
Study approval. Experiments using mice were approved by and 
conducted in accordance with guidelines of the South Australian 
(SA) Pathology/Central Adelaide Local Health Network  (CALHN) 
Animal Ethics Committee, the University of South Australia Animal 
Ethics Committee, and the Australian National Health and Medical 
Research Council (NHMRC).
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tific), and bound proteins were eluted in sample buffer and analyzed 
by immunoblotting.
Pro–VEGF-C processing. Conditioned supernatant from HEK293 
cells transfected with VEGF-C-VHD-FLAG-CT-HA, CCBE1-V5, 
FAT4-EC-HA, or untransfected controls was mixed at a 1:1:1 ratio at 
37°C. Samples were collected at various time points and analyzed by 
immunoblotting to detect the state of VEGF-C processing.
In vitro proliferation. Transfected hLECs were seeded in 96-well 
microplates at 5 × 103 cells per well with 5 replicates for each treat-
ment. Cells were cultured for 24 hours before a 16- hour starvation in 
EBM-2 supplemented with 0.5% FBS. Cells were fixed with 4% PFA 
and stained with hematoxylin immediately following serum starva-
tion (to normalize the number of cells plated) or after a 24-hour stim-
ulation with basal media (EBM-2 supplemented with 2% FBS), basal 
media containing 100 ng/mL VEGF-C, or EGM-2MV complete media 
(Lonza). Cells were quantified using ImageQuant TL Colony Count-
ing (version 8.1; GE Healthcare) software. The proliferative index rep-
resents the number of cells relative to the initial number of cells plated 
(represented as 1.0).
Transwell migration assay. Transwell assays to assess chemotactic 
cell migration were performed as previously described (64), with the 
additional step of coating the top and bottom surfaces of Transwell 
membranes with 50 μg/mL fibronectin (FN) (Roche). Cell migration 
toward basal media (EBM-2 supplemented with 0.5% FBS), basal 
media containing 100 ng/mL VEGF-C or EGM-2MV was assessed. 
Data represented as percentage of cells migrated through the mem-
brane relative to initial number of cells plated (1 × 104 cells).
Sprouting assay. 3D sprouting assays were performed as previ-
ously described (64).
In vitro flow assay. Transfected hLECs (2 × 105 cells) were seeded 
in FN-coated (50 μg/mL; Roche) μ-Slide I0.8 Luer channel slides (ibidi) 
and cultured for 24 hours in EGM-2MV to allow cells to reach conflu-
ence. Cells were then subjected to laminar flow (4 dynes/cm2) using a 
yellow-green perfusion set (ibidi) combined with the Quad Pump Sys-
tem (ibidi), or were maintained under static conditions, for 48 hours. 
Cells were fixed for 10 minutes in 4% PFA, blocked in PBS containing 
1% BSA and 0.3% Triton X-100, and stained as previously described 
(65). Nuclei were visualized using DAPI Fluoromount G (ProSciTech). 
Images were acquired using confocal microscopy as detailed above. 
Cell parameters were measured using ImageJ (60) and VE-cadherin 
staining to demarcate cell outlines. A total of 250 cells across 5 FOV 
were analyzed per condition, per experiment. The cell aspect ratio is 
defined as the major axis length relative to the minor axis length (i.e., 
length/width). For cell circularity (4π × area/perimeter2), a value of 1.0 
indicates a perfect circle, whereas a value approaching 0 indicates a 
more elongated shape.
Flow cytometry. To assess surface levels of VEGFR3, hLECs were 
transfected with control or FAT4 esiRNA, serum starved for 16 hours 
with EBM-2 supplemented with 0.5% FBS, and stimulated with 100 
ng/mL VEGF-C for 15 minutes. Immediately following treatment, 
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